BACKGROUND: Although moderate and severe COVID-19 patients have shown obstructive and restrictive disorders in pulmonary function after recovery from the disease, studies evaluating the effectiveness of rehabilitation programs that seek to improve lung function are scarce. AIM: Herein, we evaluate changes in lung function and perceived dyspnea in Covid-19 patients after undergoing 12 weeks of a PR program. DESIGN: Retrospective observational study SETTING: Cesar, Colombia Neumocesar Pneumological Center. POPULATION: 100 outpatients with a history of Covid-19 METHODS: We evaluated respiratory function using spirometry parameters, as well as the mMRC dyspnea scale for perceived dyspnea in 100 patients with a history of Covid-19. We used univariate and multivariate statistical approaches to assess changes in lung function and perceived dyspnea before and after a PR program to determine whether gender, age, height, weight, comorbidities, and oxygen delivery system affect the recovery of lung function and perceived dyspnea. RESULTS: We found that PR treatment has positive effects on respiratory pathologies caused by SARS-CoV-2 infection regardless of patient gender, indicating that rehabilitation provided benefits regardless of the physical characteristics of the patients. Both univariate and multivariate statistical analyses indicated that FVC, FEV1, FEF 25-75, and mMRC are robust diagnostic indicators of lung function recovery and perceived dyspnea. Both invasive and non-invasive positive pressure ventilatory support had deleterious effects on lung function prolongating patient recovery. CONCLUSIONS: Rehabilitation programs can benefit patients facing respiratory pathologies caused by SARS-CoV-2 infection. Additional research on the long-term effects of the sequelae of Covid-19 is needed. A large sample of patients is needed to clarify the effects of therapy on respiratory function. CLINICAL REHABILITATION IMPACT: PR programs have positive effects on patients facing respiratory pathologies caused by SARS-CoV-2 infection.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Manuela Beltran University gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data cannot be shared publicly because of a Confidentiality Agreement within the institution.